Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 942 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07564739Recruiting
Cold Plasma Treatment for Long-Lasting Wound Healing
This study tests whether a special cold plasma treatment (a type of energized gas) can safely help heal chronic wounds that haven't improved after several weeks. Cold plasma may help clean wounds and reduce bacteria, potentially speeding up healing.
OrléansAges 18 years+ - NCT07568223Recruiting
Testing artisanal bread tolerance in bread-sensitive adults
This study compares how your body responds to artisanal (handmade) bread versus conventional store-bought bread if you've experienced discomfort after eating regular bread. Researchers will track symptoms and measure markers in your blood and stool to understand why artisanal bread might be better tolerated.
BobignyAges 18–65 - NCT06349980RecruitingPhase 2
Study of three drugs for liver cancer not yet treated
This trial is testing a combination of three drugs (HLX10, HLX04, and HLX53) to find the best dose and see if they help people with advanced liver cancer who have not had systemic treatment before. The goal is to shrink tumors and improve survival.
ShanghaiAges 18 years+ - NCT07553325Recruiting
Shared Decision-Making Support for Prediabetes
This study tests a new way to help patients with prediabetes (slightly high blood sugar) make informed choices about their health using personalized risk information. The goal is to see if this approach helps patients take action to prevent or delay type 2 diabetes.
Frederick, MarylandAges 18–75 - NCT07557251RecruitingPhase 1
Combination immunotherapy for advanced liver cancer with hepatitis B
This trial tests a new combination of three drugs (BRII-5395, sintilimab, and bevacizumab) for advanced hepatocellular carcinoma (liver cancer) in patients with hepatitis B who have not responded well to previous treatments. The goal is to evaluate whether this combination is safe and effective.
BeijingAges 18–70 - NCT07554287Recruiting
Leg vs. Arm Exercise for Gestational Diabetes Management
This study tests whether exercising with your legs or arms helps manage blood sugar levels during pregnancy if you have gestational diabetes. The goal is to see which type of exercise works better and how it affects your overall health and stress during pregnancy.
Lahore, Punjab ProvinceAges 18–35 - NCT07558538RecruitingEarly Phase 1
Inhaled Growth Factor Treatment for Severe Lung Failure
This early-stage trial tests whether an inhaled medication called recombinant human keratinocyte growth factor-2 (rh-KGF-2) can help patients with acute respiratory distress syndrome (ARDS)—a serious condition where the lungs cannot deliver enough oxygen to the blood. The drug is designed to help repair lung tissue damage.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07554222RecruitingPhase 1
Safety study of IBI3013 for vitiligo and hair loss
This is an early-stage safety study of a new drug called IBI3013. The trial tests how safe the drug is and how your body processes it. It enrolls healthy volunteers first, then people with vitiligo (loss of skin color) or severe alopecia areata (patchy hair loss).
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07554495RecruitingPhase 3
Filgotinib for moderate to severe polyarticular juvenile arthritis
This trial tests filgotinib, a new medication that may help reduce joint swelling and pain in children and teens (ages 8–17) with polyarticular juvenile idiopathic arthritis—a type of childhood arthritis affecting multiple joints. You're eligible if your current arthritis medicines haven't worked well enough.
LeuvenAges 8–18 - NCT07553429RecruitingPhase 1/Phase 2
Testing a new eye injection for diabetic swelling
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
Phoenix, ArizonaAges 18 years+ - NCT05877430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug plus pembrolizumab for advanced cancers
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
Irvine, CaliforniaAges 18 years+ - NCT07549919RecruitingPhase 1
Food Effects on a New Experimental Drug in Healthy Men
This study tests how food affects how the body absorbs and processes a new experimental drug called AJ201. Researchers will give the drug to healthy men with and without food to see if it makes a difference, and they'll check for any side effects.
Los Alamitos, CaliforniaAges 18–55 - NCT07549516Recruiting
Asciminib for chronic myeloid leukemia in germany
This study tests whether the drug asciminib is safe and works well for people with chronic myeloid leukemia, compared to standard TKIs. You may join if you're newly diagnosed or have tried only one previous TKI treatment.
Baden-Baden, Baden-WurttembergAges 18–100 - NCT06745622RecruitingPhase 2
Long-term safety of HSK39297 for PNH patients
This study is for people with paroxysmal nocturnal hemoglobinuria (PNH) who have already taken the experimental drug HSK39297. It checks the long-term safety of continuing the treatment and makes sure it is still helpful.
Nanjing, JiangsuAges 18 years+ - NCT06635226RecruitingPhase 1
Safety study of ID110521156 in healthy adults
This study tests a new investigational drug called ID110521156 in healthy adults. The goal is to see if the drug is safe and how the body processes it. It may be for people who are overweight or obese.
SeoulAges 19–50 - NCT05690581RecruitingPhase 1
CM369 for advanced cancers with special immune marker in tumors
This Phase 1 study tests how safe and tolerable CM369 is in people with advanced solid tumors or blood cancers. It also looks at how the drug behaves in the body and whether it can help shrink or control cancer, especially when a tumor marker called CCR8 is present.
Guangzhou, GuangdongAges 18–75 - NCT07535099RecruitingPhase 1
Safety study of ICP-538 in healthy volunteers
This trial tests a new drug called ICP-538 in healthy people to see how safe it is and how the body processes it. It is an early-phase study that helps decide if the drug can move to testing in patients with a specific condition.
Beijing, Beijing MunicipalityAges 18–50 - NCT07540897RecruitingPhase 3
Testing ALKS 2680 for narcolepsy type 1
This study tests whether a new medication called ALKS 2680 can help people with narcolepsy type 1 stay more awake and alert during the day. Narcolepsy type 1 is a neurological condition where people fall asleep unexpectedly and may experience sudden muscle weakness.
Brandon, FloridaAges 18–70 - NCT07540910RecruitingPhase 1
Safety study of EDP-978 in healthy adults
This is an early-stage study testing a new experimental drug called EDP-978 in healthy volunteers to see if it is safe and how the body processes it. Researchers will give participants single or multiple doses and monitor for side effects and how the drug moves through the body.
San Antonio, TexasAges 18–65 - NCT07536269RecruitingPhase 2
Safety study of crinecerfont for very young children with CAH
This study tests a new medicine called crinecerfont in children under 4 years old with classic congenital adrenal hyperplasia (CAH), a condition where the body doesn't make certain hormones properly. Researchers want to learn if the medicine is safe and how it works in the body.
San Francisco, CaliforniaAges 3 months–3.9 years - NCT07541079RecruitingPhase 3
Testing a New Breast Cancer Drug for Women Who Can't Tolerate Current Therapy
This study tests giredestrant, a new hormone-blocking medication, in postmenopausal women with early-stage ER+ breast cancer who have experienced intolerable side effects from their current aromatase inhibitor therapy. The trial will measure how well you tolerate this new drug and how it affects your quality of life.
Fountain Valley, CaliforniaAges 18 years+ - NCT07538128RecruitingEarly Phase 1
New drug YSCH-01 with immunotherapy for recurrent brain cancer
This early-stage trial tests a new drug called YSCH-01, alone or combined with an immunotherapy drug (atezolizumab), for glioblastoma that has come back after previous treatment. The study places a small tube in the brain to deliver the drug directly and monitors safety and how well it works.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07525960RecruitingPhase 1
Testing NDI-5001 for X-linked Nephrogenic Diabetes Insipidus
This study tests a new drug called NDI-5001 in adult men with a specific genetic form of nephrogenic diabetes insipidus (a condition where the kidneys cannot concentrate urine properly). The trial checks whether the drug is safe, how your body handles it, and whether it might help reduce excessive urination and thirst.
Jacksonville, FloridaAges 18–55 - NCT07527221RecruitingPhase 1
Safety study of ZE74-0282 in healthy adults
This is an early-stage safety study testing a new experimental drug called ZE74-0282 in healthy volunteers. Researchers want to learn how safe the drug is and how well people tolerate it before testing it in patients with a disease.
Randwick, New South WalesAges 18–55
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 942 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.